BioSpace News Archive

Orphazyme A/S announces that, following the receipt of the negative Trend Vote by the Committee for Medicinal Products for Human Use (CHMP) as announced on February 23, 2022 (please see company announcement no. 07/2022), the Company has decided to withdraw its European Marketing Authorisation Application (MAA) for arimoclomol for the treatment of Niemann-Pick disease Type C.

Aravive, Inc., a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced the appointment of industry veteran, Scott Dove, Ph.D., as Chief Operating Officer.

Matinas BioPharma announced that Jerry Jabbour, Chief Executive Officer, has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest.

Science 37 Holdings, Inc. today reported its financial results for the quarter and full year ended December 31, 2021.

Lantern Pharma Inc. announced that its Board of Directors has authorized an extension through July 31, 2022 of Lantern’s existing share repurchase program to acquire up to $7 million of the Company’s common stock.

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that it is expanding its mRNA pipeline with two new development programs.

2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the fourth quarter and year ended December 31, 2021.

Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced results from its Phase 2 study of lucinactant (KL4 surfactant) for patients with severe COVID-19 associated acute respiratory distress syndrome (ARDS) and lung injury.

Decibel Therapeutics announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in the following upcoming virtual investor conferences in March.

Natera, Inc. today announced that a study 1 reporting on the performance of donor-derived cell-free DNA (dd-cfDNA) testing using the Prospera™ technology for the assessment of pancreas graft rejection in simultaneous pancreas-kidney (SPK) transplantation has been published in Transplantation, the official Journal of The Transplantation Society.